Tailoring treatment in myeloma: are there clues from biology?
- 10 March 2015
- journal article
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 8 (1) , 11-15
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor LoadJournal of Clinical Oncology, 2013
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 StudiesBlood, 2012
- Genomic analysis of high-risk smoldering multiple myelomaHaematologica, 2012
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pBlood, 2012
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)Journal of Clinical Oncology, 2010
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008